Seyltx is focused on developing innovative therapies for refractory chronic cough, leveraging a deep understanding of the brain's neural pathways. Their lead program, Ifenprodil, aims to be a first-in-class oral treatment for this condition. The company employs a unique development platform that maps newly understood causal neural pathways to therapies with established safety profiles, allowing for targeted interventions. This approach is bolstered by their expertise in neuroscience, which has led to significant discoveries in the field, including the identification of specific proteins involved in chronic cough. 

To enhance their drug development process, Seyltx utilizes a strategy that emphasizes the identification of existing compounds that can effectively target the cough reflex pathway. This method not only accelerates the initial stages of development but also minimizes risks by leveraging pre-existing safety data from previous trials. Additionally, Seyltx employs robust intellectual property strategies to protect their discoveries, ensuring that their innovative solutions can continue to provide long-term value to patients. This comprehensive approach positions Seyltx as a leader in the development of effective therapies for chronic cough, with a commitment to maximizing patient benefits through efficient drug development processes.

United States

Seyltx is a late clinical-stage pharmaceutical company leveraging new insights into how the brain functions to selectively target the "master switch" of the cough reflex to address refractory chronic cough - a condition that 4-5 million people in the US alone suffers from.

Seyltx

Company Details